United Capital Financial Advisers LLC Has $249,000 Stake in Aerie Pharmaceuticals, Inc. (AERI)

United Capital Financial Advisers LLC maintained its position in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,500 shares of the company’s stock at the end of the first quarter. United Capital Financial Advisers LLC’s holdings in Aerie Pharmaceuticals were worth $249,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. BlackRock Inc. increased its position in Aerie Pharmaceuticals by 113,376.8% in the first quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock valued at $117,951,000 after buying an additional 2,598,596 shares during the period. State Street Corp increased its position in Aerie Pharmaceuticals by 36.9% in the fourth quarter. State Street Corp now owns 820,644 shares of the company’s stock valued at $31,059,000 after buying an additional 221,146 shares during the period. FMR LLC increased its position in Aerie Pharmaceuticals by 178.7% in the first quarter. FMR LLC now owns 320,500 shares of the company’s stock valued at $14,535,000 after buying an additional 205,500 shares during the period. Vanguard Group Inc. increased its position in Aerie Pharmaceuticals by 7.1% in the first quarter. Vanguard Group Inc. now owns 1,392,525 shares of the company’s stock valued at $63,151,000 after buying an additional 92,463 shares during the period. Finally, Handelsbanken Fonder AB bought a new position in Aerie Pharmaceuticals during the first quarter valued at approximately $3,311,000. 92.01% of the stock is currently owned by hedge funds and other institutional investors.

Aerie Pharmaceuticals, Inc. (NASDAQ AERI) traded up 2.40% during trading on Friday, reaching $55.50. The company had a trading volume of 222,224 shares. The company’s 50-day moving average is $54.10 and its 200 day moving average is $47.17. Aerie Pharmaceuticals, Inc. has a 52 week low of $16.61 and a 52 week high of $59.50. The firm’s market capitalization is $1.87 billion.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Tuesday, May 2nd. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.74) by $0.02. Equities analysts anticipate that Aerie Pharmaceuticals, Inc. will post ($2.56) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.chaffeybreeze.com/2017/07/30/united-capital-financial-advisers-llc-has-249000-stake-in-aerie-pharmaceuticals-inc-aeri-updated-updated-updated.html.

AERI has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $69.00 target price on shares of Aerie Pharmaceuticals in a research note on Thursday, May 25th. BidaskClub downgraded Aerie Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 17th. Canaccord Genuity reissued a “buy” rating and set a $56.00 target price on shares of Aerie Pharmaceuticals in a research note on Tuesday, April 18th. Stifel Nicolaus reissued a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Friday, May 26th. Finally, Aegis reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Aerie Pharmaceuticals in a research note on Thursday, April 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $66.08.

In related news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $55.95, for a total value of $1,119,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 9.36% of the company’s stock.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply